Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05423340 · ClinicalTrials.gov registry record · NA
Effect of E-Liquid Flavor on Respiratory Symptoms in People Using Electronic Nicotine Delivery Systems
A NA study, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 163
- Enrollment target
NCT05423340: Completed NA study, sponsored by Roswell Park Cancer Institute.
NCT05423340 is a NA study that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 163 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05423340, a NA study, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 163 participants
- Enrollment target
Study Summary
This is a randomized, parallel-group open-label trial to evaluate respiratory symptoms in ENDS users switching from banned flavors to a non-banned flavor (tobacco) or 'tobacco free' nicotine pouches.
Primary Outcome
Oxidative stress and inflammation in plasma using ELISA.
Interventions
- OTHER E-cigarette Flavor
- OTHER Tobacco Free Nicotine Pouch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 163 participants |
| Start Date | 2022-06-12 |
| Est. Completion | 2024-10-03 |
| Phase | NA |
What the finished NCT05423340 record still lists
NCT05423340 is an interventional study that assigns participants to a tested intervention. The registered 163 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 2 interventions - of which E-cigarette Flavor is the first listed.
NCT05423340 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05423340 about?
NCT05423340 is a clinical study titled "Effect of E-Liquid Flavor on Respiratory Symptoms in People Using Electronic Nicotine Delivery Systems". This is a randomized, parallel-group open-label trial to evaluate respiratory symptoms in ENDS users switching from banned flavors to a non-banned flavor (tobacco) or 'tobacco free' nicotine pouches.
What is the current status of trial NCT05423340?
This trial is currently completed. It is a NA study. The enrollment target is 163 participants. The study started on 2022-06-12. Estimated completion is 2024-10-03.
What interventions are being tested in trial NCT05423340?
The interventions under investigation include: E-cigarette Flavor (OTHER), Tobacco Free Nicotine Pouch (OTHER).
Who is sponsoring clinical trial NCT05423340?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05423340's enrollment target sits among peer trials
163 627th of 2000 higher than 1,374 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03180268 · 163 participants · Phase 3
Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
- NCT04862221 · 163 participants · Phase 2
TReatment for ImmUne Mediated PathopHysiology
- NCT05702229 · 163 participants · Phase 2
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
- NCT06137118 · 163 participants · Phase 1
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI